(Headquarters: Paramus, New Jersey; President: Yukiteru Sugiyama), a biopharmaceutical leader in rare disease and subsidiary of Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan; President: Toru ...

New data suggest that givinostat treatment may slow the decline of upper limb function in boys with Duchenne muscular dystrophy compared with ...

Data from BASECAMP expected in Q1 2027TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX ...

Oculopharyngeal muscular dystrophy typically begins around age 65, and one man is watching his father's health history repeat ...

Limb-Girdle Muscular Dystrophy (LGMD) affects an estimated 17,000 Americans and 580,000 people worldwide.

For Duchenne and Becker muscular dystrophies, muscle biopsy may show whether dystrophin, a muscle protein, is missing or abnormal, and DNA testing is used to analyze the condition of the related gene.

Dystrophy is any condition in which a part of the body weakens or wastes away. In muscular dystrophy, the weakness is in the muscles. An inherited genetic mistake prevents the body from making a ...

I have been researching creatine. In healthy individuals, it improves muscle strength and performance in short-duration, high ...

Kyoto, Japan, October 1, 2026 - Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto; President, Toru Nakai) announced the five-year efficacy and safety data for brogidirsen (NS-089/NCNP-02 ...

Satellos Bioscience Inc. announced that enrollment has been completed for BASECAMP, the company's Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy (DMD) ...

The Muscular Dystrophy Association applauds the United States Senate for passing the House’s version of the ACT for ALS ...